

Referenser

Genombrott i Alzheimerbehandling?

1. Nenad Bogdanovic, Oskar Hansson, Henrik Zetterberg, Hans Basun, Martin Ingelsson, Lars Lannfelt, Kaj Blennow. Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden. *Läkartidningen* 2020;117FZHM. (117):1–7.
2. Priller C, Bauer T, Mitteregger G, Krebs B, Kretschmar HA, Herms J. Synapse Formation and Function Is Modulated by the Amyloid Precursor Protein. *J Neurosci*. 2006 Jul 5;26(27):7212–21.
3. Decourt B, Boumelhem F, Pope ED, Shi J, Mari Z, Sabbagh MN. Critical Appraisal of Amyloid Lowering Agents in AD. *Curr Neurol Neurosci Rep*. 2021 Aug;21(8):39.
4. Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, et al. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. *Front Immunol*. 2020 Aug 28;11:1986.
5. Dr. Patrizia Cavazzoni. FDA's Decision to Approve New Treatment for Alzheimer's Disease [Internet]. U.S. FOOD & DRUG ADMINISTRATION. 2021. Available from: <https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease>
6. Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. *JAMA Neurol*. 2022 Jan 1;79(1):13.
7. Drar tillbaka ansökan om EU-godkännande [Internet]. *Läkemedelsvärlden*. 2022 [cited 2023 Jan 13]. Available from: <https://www.lakemedelsvarlden.se/drar-tillbaka-ansokan-om-eu-godkannande-av-aduhelm/>
8. Oskar Bosson. BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in the EU [Internet]. <https://www.bioarctic.se/>. 2023. Available from: <https://www.bioarctic.se/en/bioarctics-partner-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-the-eu-5933/#>
9. Reardon S. FDA approves Alzheimer's drug lecanemab amid safety concerns. *Nature*. 2023 Jan 12;613(7943):227–8.
10. Söllvander S, Nikitidou E, Gallasch L, Zyśk M, Söderberg L, Sehlin D, et al. The A β protofibril selective antibody mAb158 prevents accumulation of A β in astrocytes and rescues neurons from A β -induced cell death. *J Neuroinflammation*. 2018 Dec;15(1):98.
11. Decourt B, Boumelhem F, Pope ED, Shi J, Mari Z, Sabbagh MN. Critical Appraisal of Amyloid Lowering Agents in AD. *Curr Neurol Neurosci Rep*. 2021 Aug;21(8):39.
12. Koike H, Iguchi Y, Sahashi K, Katsuno M. Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. *Molecules*. 2021 Aug 22;26(16):5091.

13. Caughey B, Lansbury PT. P ROTOFIBRILS , P ORES , F IBRILS, AND N EURODEGENERATION : Separating the Responsible Protein Aggregates from The Innocent Bystanders. *Annu Rev Neurosci*. 2003 Mar;26(1):267–98.
14. Lars Lannfelt. Alzheimerbehandling visar unika resultat [Internet]. 2018 [cited 2023 Jan 13]. Available from: <https://www.uu.se/nyheter/artikel/?id=11424&typ=>
15. Collaborations and partners [Internet]. Available from: <https://www.bioarctic.se/en/collaborations-and-partners-1892/>
16. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer's Disease. *N Engl J Med*. 2023 Jan 5;388(1):9–21.
17. Scientists tie third clinical trial death to experimental Alzheimer's drug [Internet]. 2022 [cited 2023 Jan 16]. Available from: <https://www.science.org/content/article/scientists-tie-third-clinical-trial-death-experimental-alzheimer-s-drug>